BMC Infectious Diseases

Table 2 Phenotypic and molecular characteristics (clonality and drug resistance genes) of 26 N. gonorrhoeae isolates detected during the period 2010–2012 in Switzerland

From: Characterization of Neisseria gonorrhoeaeisolates detected in Switzerland (1998–2012): emergence of multidrug-resistant clones less susceptible to cephalosporins

Isolate	Year	ST (Genogroup)	PP^a	Minimum inhibitory concentration, mg/L^b								PBP1 (ponA)	PBP2 (penA)^c	TEM	GyrA	ParC	PorB (penB)	MtrR	mtrRpromoter	L4 (rplD)	L22 (rplV)	23S rRNA (4 copies)	ermA/B/C/F and mefA	tet(M)
				PEN	CFX	CRO	CIP	AZT	TET	SPE	GEN
1820606	2010	495	+	6	≤0.016	0.006	0.006	0.38	96	12	8	L421P	XII	TEM-1	WT	WT	G120K, A121D	A39T, L47P	WT	WT	WT	All WT	-	+
1865296	2010	292	-	0.25	≤0.016	0.006	2	0.25	0.5	6	4	L421P	V	-	S91F, D95G	S87R	A121S	WT	A deletion	WT	WT	All WT	-	-
1872778	2010	2861 (G225)	-	0.38	0.047	0.032	>32	0.25	0.75	4	4	L421P	XII	-	S91F, D95G	S87R	G120K, A121D	WT	A deletion	WT	WT	All WT	-	-
1832086	2010	1407 (G1407)	-	0.5	0.19	0.047	6	0.25	1.5	8	6	L421P	XXXIV	-	S91F, D95G	S87R	G120K, A121N	WT	A deletion	WT	WT	All WT	-	-
1859198	2010	225 (G225)	-	0.5	0.047	0.032	>32	0.38	1.5	8	8	L421P	XII	-	S91F, D95G	S87R	G120K, A121D	WT	A deletion	WT	WT	All WT	-	-
1910312	2010	2992 (G2992)	-	0.094	≤0.016	0.003	≤0.002	0.25	0.38	6	4	WT	II	-	WT	WT	WT	A39T, R44H	WT	WT ^d	WT	All WT	-	-
1869994	2010	1766	+	6	≤0.016	0.006	0.75	≤0.016	6	6	4	L421P	IIg	TEM-1	S91F, D95A	S87N	G120D	WT	A deletion	WT	WT	All WT	-	+
1912168	2010	8676	+	32	≤0.016	≤0.002	3	0.032	8	4	4	L421P	II	TEM-1	S91F, D95G	S87R	G120K, A121D	WT	WT	WT	WT	All WT	-	+
1922603	2011	3149 (G1407)	-	0.38	0.19	0.047	16	0.25	1.5	8	6	L421P	XXXIV	-	S91F, D95G	S87R	G120K, A121N	WT	A deletion	WT	WT	All WT	-	-
1996003	2011	3611	+	12	≤0.016	0.008	>32	0.125	96	8	4	L421P	XIX	TEM-1	S91F, D95A	S87N, E91K	G120K, A121G	A39T	WT	WT	WT	All WT	-	+
2017570	2011	1407 (G1407)	-	0.38	0.125	0.023	12	0.38	1	8	6	L421P	XXXIV	-	S91F, D95G	S87R	G120K, A121N	WT	A deletion	WT	WT	All WT	-	-
2004277	2011	8708	-	0.125	≤0.016	≤0.002	≤0.002	0.25	0.5	8	4	WT	II	-	WT	WT	WT	G45D	WT	WT	WT	All WT	-	-
1973517	2011	4232	-	0.19	≤0.016	0.003	≤0.002	0.19	16	8	6	WT	II	-	WT	WT	A121S	G45D	WT	WT ^d	WT	All WT	-	+
1929711	2011	2992 (G2992)	-	0.064	≤0.016	0.003	≤0.002	0.25	0.38	8	6	WT	II	-	WT	WT	WT	A39T, R44H	WT	WT ^d	WT	All WT	-	-
1944251	2011	2992 (G2992)	-	0.047	≤0.016	0.003	≤0.002	0.25	0.25	6	4	WT	II	-	WT	WT	WT	A39T, R44H	WT	WT ^d	WT	All WT	-	-
1954615	2011	8707	+	12	≤0.016	0.004	1.5	0.064	24	2	4	L421P	XIX	TEM-1	S91F, D95A	S87R	A121S	A39T	WT	WT	WT	All WT	-	+
1946253	2011	1407 (G1407)	-	0.38	0.125	0.032	32	0.75	1.5	8	6	L421P	XXXIV	-	S91F, D95G	S87R	G120K, A121N	WT	A deletion	WT	WT	All WT	-	-
2036196	2012	5528	+	>32	≤0.016	0.004	12	0.25	64	8	4	WT	II	TEM-135	S91F, D95G	D86N	G120K, A121D	WT	WT	WT	WT	All WT	-	+
2086772	2012	8827	+	3	≤0.016	≤0.002	2	0.023	16	6	6	L421P	XIX	TEM-1	S91F, D95A	S87N, E91K	G120K, A121D	A39T	WT	WT	WT	All WT	-	+
2096513	2012	7616	-	0.047	≤0.016	0.002	≤0.002	0.25	0.38	6	8	WT	II	-	WT	WT	WT	A39T, R44H	WT	WT ^d	WT	All WT	-	-
2112655	2012	8826	-	0.38	0.094	0.023	24	0.125	0.25	3	6	L421P	XXXIV	-	S91F, D95G	S87R	G120K, A121N	WT	A deletion	WT	WT	All WT	-	-
2119347	2012	3378	-	0.38	0.094	0.032	16	0.5	1	8	12	L421P	XXXIV	-	S91F, D95G	S87R	G120K, A121N	WT	A deletion	WT	WT	All WT	-	-
2121127	2012	8825	-	0.125	≤0.016	0.003	0.75	≤0.016	0.25	2	1	L421P	II	-	S91F, A92S, D95N	E91G	G120K, A121D	A39T	WT	WT	WT	All WT	-	-
2129562	2012	437 (G225)	-	0.25	0.023	0.023	24	0.19	0.5	3	8	L421P	V	-	S91F, D95G	S87R	G120K, A121D	WT	A deletion	WT	WT	All WT	-	-
2131245	2012	8410	+	16	0.023	0.006	3	0.064	8	8	6	WT	XXI-like	TEM-135	S91F, D95A	S87R	A121G	A39T	WT	WT	WT	All WT	-	+
2132307	2012	3149 (G1407)	-	0.38	0.094	0.023	32	0.38	1	8	8	L421P	XXXIV	-	S91F, D95G	S87R	G120K, A121N	WT	A deletion	WT	WT	All WT	-	-

Note. WT, wild-type; +, positive; -, negative.
^aPenicillinase producers according to the cefinase disk test (Oxoid) and nitrocefin test.
^bAbbreviations and MIC interpretation according to the EUCAST criteria [26]: penicillin (PEN; sensible, S ≤ 0.06 mg/L); ceftriaxone (CRO; S ≤ 0.125 mg/L); cefixime (CFX; S ≤ 0.125 mg/L); ciprofloxacin (CIP; S ≤ 0.03 mg/L); azithromycin (AZT; S ≤0.25 mg/L); tetracycline (TET; S ≤ 0.25 mg/L); spectinomycin (SPE; S ≤ 64 mg/L); gentamicin (GEN; criteria not available).
^cThe characteristics of the PBP2 patterns II, V, XII, and XIX were described by Whiley DM et al. [16], those of pattern XXXIV by Hess D et al. [28], and pattern IIg by Takahashi et al. [29]. Pattern XXI-like does not have -574N and A575V as in the XXI [16].
^dThe L4 of these Ng isolates possessed three substitutions (i.e., V125A, A147G, R157Q) that have no recognized impact on the macrolides resistance.

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com